Cargando…
Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
Diffuse intrinsic pontine glioma (DIPG) is the most lethal tumor involving the pediatric central nervous system. The median survival of children that are diagnosed with DIPG is only 9 to 11 months. More than 200 clinical trials have failed to increase the survival outcomes using conventional cytotox...
Autores principales: | Liu, Guohao, Qiu, Yanmei, Zhang, Po, Chen, Zirong, Chen, Sui, Huang, Weida, Wang, Baofeng, Yu, Xingjiang, Guo, Dongsheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9502387/ https://www.ncbi.nlm.nih.gov/pubmed/36145510 http://dx.doi.org/10.3390/pharmaceutics14091762 |
Ejemplares similares
-
Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma
por: Chen, Yujia, et al.
Publicado: (2023) -
Tenascin-C can Serve as an Indicator for the Immunosuppressive Microenvironment of Diffuse Low-Grade Gliomas
por: Zhang, Po, et al.
Publicado: (2022) -
Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma
por: Bredlau, Amy Lee, et al.
Publicado: (2017) -
Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma
por: Flannery, Patrick C., et al.
Publicado: (2018) -
Diffuse intrinsic pontine glioma: poised for progress
por: Warren, Katherine E.
Publicado: (2012)